Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus

Publikation

Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus

Wissenschaftlicher Artikel/Review - 20.03.2014

Wuerzner Gregoire, Pechère-Bertschi Antoinette, Baumgartner Iris, Jacob Augustinus L, Burnier Michel, Qanadli Salah D, Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Sticherling Christian, Kaiser Christophe, Waeber Bernard, Muller Olivier, Erne Paul, Cook Stéphane, Sudano Isabella, Lüscher Thomas F, Noll Georg, Kaufmann Urs, Rickli Hans, Swiss Society of Cardiovascular and Interventional Radiology

Zitation

Wuerzner G, Pechère-Bertschi A, Baumgartner I, Jacob A, Burnier M, Qanadli S, Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Sticherling C, Kaiser C, Waeber B, Muller O, Erne P, Cook S, Sudano I, Lüscher T, Noll G, Kaufmann U, Rickli H, Swiss Society of Cardiovascular and Interventional Radiology. Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus. Swiss Med Wkly 2014; 144:w13913.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Swiss Med Wkly 2014; 144

Veröffentlichungsdatum

20.03.2014

eISSN (Online)

1424-3997

Seiten

w13913

Kurzbeschreibung/Zielsetzung

Transcatheter (or percutaneous) renal denervation is a novel technique developed for the treatment of resistant hypertension. So far, only one randomised controlled trial has been published, which has shown a reduction of office blood pressure. The Swiss Society of Hypertension, the Swiss Society of Cardiology, The Swiss Society of Angiology and the Swiss Society of Interventional Radiology decided to establish recommendations to practicing physicians and specialists for good clinical practice. The eligibility of patients for transcatheter renal denervation needs (1.) confirmation of truly resistant hypertension, (2.) exclusion of secondary forms of hypertension, (3.) a multidisciplinary decision confirming the eligibility, (4.) facilities that guarantee procedural safety and (5.) a long-term follow-up of the patients, if possible in cooperation with a hypertension specialist. These steps are essential until long-term data on safety and efficacy are available.